Sign In
REPH.US
id: 334
E.D. Pennsylvania
Court
17 Jul 2017
Class period Start
23 May 2018
Class period End
08 Oct 2022
Claim deadline
Recro Pharma agreed to pay $1.4 million to settle a securities class action lawsuit accusing the Company of deceiving investors about material information.
The original complaint alleged that the Company and its Leaders misled investors through a series of public statements regarding Recro’s target opportunities that allegedly inflated Recro’s stock price, in particular, they misrepresented and/or omitted Key Opinion Leader concerns about the drug IV meloxicam.

Recro Pharma agreed to settle with investors to avoid further litigation.
Case Status
Accepting Late Claims
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Plaintiffs
John Alberici
Attorneys
Pomerantz LLP, Kaskela Law LLC, Bronstein, Gewirtz & Grossman LLC
Judge
Hon. Michael M. Baylson
Administrator
Strategic Claims Services
Court hearing date
26 October 2022
+$1,400,000
Cash Settlement Amount

Recro Pharma, Inc.

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molec...

    Ticker
    REPH.US
    ISIN
    US75629F1093
    CIK
    1588972
    Sector
    Healthcare
    Industry
    Pharmaceuticals
    Country
    USA
    Address
    1 E. Uwchlan Avenue, Exton, PA, United States, 19341